MyoKar­dia re­claims US roy­al­ty rights to heart drugs, com­plet­ing con­scious un­cou­pling from Sanofi

In Jan­u­ary, MyoKar­dia dis­closed that Sanofi was walk­ing away from their heart drug part­ner­ship forged in 2014. On Thurs­day, the San Fran­cis­co-based biotech said it had re­gained the US roy­al­ty rights to two prod­ucts from the French drug­mak­er for $50 mil­lion up­front.

MyoKar­dia $MYOK will al­so pay an ad­di­tion­al $30 mil­lion next year for the rights to the ex­per­i­men­tal drugs: mava­camten and MYK-224.  Un­der the terms of the for­mer deal with Sanofi $SNY, the Parisian com­pa­ny was el­i­gi­ble to re­ceive tiered roy­al­ties rang­ing from 5% to 10% on US sales of the two drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.